Technical Data
I8439-28L
IL17F (Interleukin-17F, IL-17F, Cytokine ML-1, Interleukin-24, IL-24, IL24)
Description:
nterleukin 17 (IL-17) is a pro-inflammatory cytokine produced by a subset of T helper cells that develops distinct from the Th1- and Th2- cell differentiation pathways. IL-17, also known as CTLA-8, stimulates induction of other pro-inflammatory cytokines TNF alpha, IL-1 beta, IL-6, and IL-8, and reports strongly suggest the involvement of IL-17 in several chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and multiple sclerosis. TGF- (differentiation) and IL-23 (expansion) are required for induction and maintenance of Th17 (IL-17 producing) cells, which in turn induce the other pro-inflammatory cytokines. IL-17 (~32kD) protein is produced and exists as a homo-dimer, has homology to a herpes virus early protein, is one of the six members (IL-17A-F) of this cytokine family, and is well characterzed and highly expressed by activated effector memory T cells.

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 0.2-2ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG1,k11E241Affinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanMouse
Concentration:
~0.5mg/ml
Immunogen:
Recombinant corresponding to full-length human IL-17F.
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, 0.05% BSA, 0.05% sodium azide.
Specificity:
Recognizes human IL-17F.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Chen Z and O'Shea JJ 2008 Immunol Res 41: 87-102 2. Mangan PR et al 2006 Nature 441: 231-234 3. Veldhoen M et al 2006 Immunity 24:179-189.